Ofloxacin:<i>In Vitro</i>Activity Against Recently Isolated Gram-Negative Bacterial Strains

Chiaradia, V.; Pascoli, L; Mucignat, Giorgio; Rubli, F.; Santini, G

doi:10.1080/1120009x.1989.11738869

Journal of Chemotherapy

1989

DOI: 10.1080/1120009x.1989.11738869

|View full text |Cite

Ofloxacin:In VitroActivity Against Recently Isolated Gram-Negative Bacterial Strains

V. Chiaradia¹,

L Pascoli²,

Giorgio Mucignat³

et al.

Abstract: The activity of ofloxacin was determined against 117 Enterobacteriaceae, 13 Acinetobacter var, anitratus, 124 Pseudomonas aeruginosa in comparison with other antibiotics. Its activity was very high: against Enterobacteriaceae the minimum inhibitory concentration (MIC)50 was 0.125 micrograms/ml, the MIC90 1 micrograms/ml, and the geometric mean (GM) was 0.4 micrograms/ml against Acinetobacter var. anitratus the MIC50 1 micrograms/ml, MIC90 4 micrograms/ml, GM 1.7 micrograms/ml. Unlike other authors we found tha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Review of Preclinical Studies with Ofloxacin

Sanders

1992

Clinical Infectious Diseases

View full text Add to dashboard Cite

Most Enterobacteriaceae, enteropathogens, and fastidious gram-negative bacteria are highly susceptible to ofloxacin, a new tricyclic fluoroquinolone. Aerobic gram-negative bacilli and gram-positive bacteria are generally not as susceptible to ofloxacin. Obligate anaerobes are generally resistant to ofloxacin, while many mycobacteria, chlamydiae, legionellae, and mycoplasmas are susceptible. Ofloxacin is generally less active than ciprofloxacin against gram-negative bacteria, is similarly active against gram-positive bacteria, mycobacteria, legionellae, and mycoplasmas, and is more active against chlamydiae. However, numerous animal studies have shown these two fluoroquinolones to be similar. Ofloxacin inhibits DNA synthesis, is rapidly bactericidal, and is 1,000-2,400 times more potent against prokaryotic gyrase than against eukaryotic gyrase. The bactericidal effect of ofloxacin is not completely neutralized by inhibitors of protein or RNA synthesis. Resistance to ofloxacin arises from mutations within chromosomal genes involved with DNA gyrase and drug permeation. Selection of resistant mutants by ofloxacin is not as frequent as that seen with nalidixic acid. However, due to the cross-resistance between ofloxacin and other fluoroquinolones, all of these drugs should be used judiciously to preserve their clinical utility.

show abstract

Review of Preclinical Studies with Ofloxacin

Sanders

1992

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ofloxacin:In VitroActivity Against Recently Isolated Gram-Negative Bacterial Strains

Cited by 1 publication

References 6 publications

Review of Preclinical Studies with Ofloxacin

Review of Preclinical Studies with Ofloxacin

Contact Info

Product

Resources

About